> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Reports 4.8% Passive Stake In BioCryst, Measured At September's End
- URL: https://www.bullished.co/state-street-reports-4-8-passive-stake-in-biocryst-measured-at-septembers-end-e3b2dacf/
- Published: 2026-11-10T12:25:04.000Z
- Updated: 2026-11-10T12:25:04.000Z
- Description: The holding covered 12,294,412 shares, while BioCryst raised its revenue outlook and pulled back from internal research.
- Author: Matteo Parrino
- Tags: SEC Filings, BCRX, Industry: Healthcare

State Street reported a [4.8% passive stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000622/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [BioCryst Pharmaceuticals](https://www.bullished.co/tag/bcrx/), which develops and sells treatments for hereditary angioedema and other rare diseases, in an SEC ownership disclosure filed Tuesday. The position covered 12,294,412 common shares as of September 30, 2026—not a holding measured on the filing date.

## A Passive Position, Shared Powers

State Street certified that the securities were bought and held as part of its ordinary business, rather than to alter or influence BioCryst's control. The disclosure measures ownership under the SEC's beneficial-ownership rules.

State Street had [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000622/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 11,692,962 shares and shared authority to dispose of all 12,294,412 shares. It reported no sole authority to vote or dispose of the stock.

## Higher Outlook, Lower Shares

BioCryst [raised its revenue outlook](https://sg.finance.yahoo.com/news/biocryst-pharmaceuticals-bcrx-raised-outlook-071106696.html?ref=bullished.co) for full-year 2026 after third-quarter revenue of $180.3 million and net income of $37.9 million. It forecast operating costs of $420 million to $440 million, excluding certain accounting expenses.

BCRX shares were down about 18% over 90 days as of Tuesday's original report. BioCryst's market value was $2.0 billion as of 7:20 a.m. ET Tuesday.

The company discontinued its internal drug-discovery programs and closed its Birmingham research facility. Bailey Pemberton, writing in Yahoo Finance commentary, argued that the retreat made [external deals and royalties](https://sg.finance.yahoo.com/news/biocryst-pharmaceuticals-bcrx-raised-outlook-071106696.html?ref=bullished.co) central to its rare-disease portfolio. Pemberton identified competition arriving faster than expected for ORLADEYO and debt associated with the Astria deal as risks to the company's future flexibility.

## ORLADEYO Anchors The Drug Business

ORLADEYO, BioCryst's main product, is a daily oral capsule used to prevent attacks of hereditary angioedema, a rare genetic disorder that causes repeated swelling. It is approved in the United States and multiple other markets; a pellet version is also approved in the United States for children aged 2 to under 12.

BioCryst uses its own commercial teams in the United States and other markets, alongside licensing and distribution partners in Japan, Latin America and parts of Europe and Asia. It also sells RAPIVAB, an intravenous flu medicine containing peramivir, and is testing drug candidates including navenibart, a hereditary-angioedema treatment in late-stage trials.

State Street's reported position is passive: its certification ties the holding to ordinary business activity, not an effort to influence control of BioCryst.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: BIOCRYST PHARMACEUTICALS INC (BCRX)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000622/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value?](https://sg.finance.yahoo.com/news/biocryst-pharmaceuticals-bcrx-raised-outlook-071106696.html?ref=bullished.co) — Yahoo Finance
- [BioCryst Pharmaceuticals, Inc. (BCRX) Seasonal Returns Chart - Yahoo Finance](https://ca.finance.yahoo.com/quote/BCRX/seasonality/?ref=bullished.co) — Yahoo Finance

### More on BioCryst Pharmaceuticals

- [BioCryst Pharmacy Switch Inflates ORLADEYO Quarter](https://www.bullished.co/biocryst-pharmacy-switch-inflates-orladeyo-quarter-1a432655/)
- [BioCryst Raises Revenue Outlook To $715 Million To $730 Million As Quarterly Profit Triples](https://www.bullished.co/biocryst-raises-revenue-outlook-to-715-million-to-730-million-as-quarterly-profit-triples-6bdc8ffc/)

[All BioCryst Pharmaceuticals (BCRX) coverage →](https://www.bullished.co/tag/bcrx/)